Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat
metastatic and unresectable melanoma. Clinical trials have shown increased overall
survival and progression-free survival in patients treated with Vemurafenib. However,
cutaneous adverse events are common during treatment. We report fi ve cases of
metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its
cutaneous adverse events. Dermatologists and oncologists need to be aware of possible
skin changes caused by this medication, which is increasingly employed in melanoma
treatment. Monitoring of patients during therapy is important for early treatment of
adverse cutaneous cutaneous adverse events, improvement in quality of life and
adherence to treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.